Clinical characteristics of patients with untreated CML, analyzed for SHP-1 expression
| . | Optimal responders . | Suboptimal responders . | Failure responders . |
|---|---|---|---|
| No. of patients | 35 | 15 | 10 |
| M/F, n/n | 21/14 | 12/3 | 6/4 |
| Age, y, median (range) | 48 (22-70) | 40 (25-61) | 62 (35-70) |
| WBC count, × 103/μL, median (range) | 80 (27-300) | 88 (48-260) | 93 (25-246) |
| PLT count, × 103/μ, median (range) | 325 (34-995) | 284 (123-691) | 439 (145-748) |
| Sokal score low/intermediate/high | 18/12/5 | 8/5/2 | 2/6/2 |
| BCR/ABL at baseline, IS, median (range) | 123 (13-295) | 130 (12-245) | 130 (48-158) |
| SHP-1/ABL at baseline, mRNA copy ratio, median (range) | 5.4 (2.4-9.5) | 4 (1.3-7.3) | 3.1 (2.2-5.2) |
| . | Optimal responders . | Suboptimal responders . | Failure responders . |
|---|---|---|---|
| No. of patients | 35 | 15 | 10 |
| M/F, n/n | 21/14 | 12/3 | 6/4 |
| Age, y, median (range) | 48 (22-70) | 40 (25-61) | 62 (35-70) |
| WBC count, × 103/μL, median (range) | 80 (27-300) | 88 (48-260) | 93 (25-246) |
| PLT count, × 103/μ, median (range) | 325 (34-995) | 284 (123-691) | 439 (145-748) |
| Sokal score low/intermediate/high | 18/12/5 | 8/5/2 | 2/6/2 |
| BCR/ABL at baseline, IS, median (range) | 123 (13-295) | 130 (12-245) | 130 (48-158) |
| SHP-1/ABL at baseline, mRNA copy ratio, median (range) | 5.4 (2.4-9.5) | 4 (1.3-7.3) | 3.1 (2.2-5.2) |
WBC indicates white blood cell; and PLT, platelet.